Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
about
Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the Brazilian Group of Flow Cytometry (GBCFLUX).Standardisation of minimal residual disease in multiple myeloma.Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Myeloma minimal residual disease testing in the United States: Evidence of improved standardization.Current applications of multiparameter flow cytometry in plasma cell disorders.Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.Minimal residual disease in multiple myeloma: Benefits of flow cytometry.Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.Polychromatic flow cytometry is more sensitive than microscopy in detecting small monoclonal plasma cell populations.Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.
P2860
Q38679490-9BDD0358-6C81-47A0-8FFF-D2018CDD2C4FQ38881884-3567F0CF-2FCB-4497-9A74-7FBA631C3DC3Q39410899-1040A781-5CF3-446D-8D07-9904F0BA5B8BQ40968571-10FA8B09-2C19-4B2D-9089-E152AE8DF094Q42050819-B848B191-65C9-4206-8EB0-3BE8C7F7527AQ46809405-653B7BBE-E55D-4EE1-A92B-6C1B2D693813Q47110039-DCADBD57-9443-4444-A795-52D781DF4808Q47281717-FB31A15D-EA7A-4B3F-8EB3-14FBA60496EFQ47314920-0BE88D46-89C5-4AA9-B213-E2F4B9A7C7ABQ47744241-9267AFFC-B35E-4E70-B225-E01DE1DA6083Q49641900-1B42DF5C-8812-43E7-B287-C0BCF14F34EFQ50589659-78A528AC-0FC4-4967-AC19-2FC228ACB00FQ50609883-411C43CC-7B39-4D20-A623-F476003870A5Q51804210-C5C59600-0F1B-426F-ADBE-9CEFE3B3DA05Q52715556-D6432077-67B3-426B-AACD-C556FF476DF4
P2860
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Consensus guidelines for myelo ...... staining and data acquisition.
@ast
Consensus guidelines for myelo ...... staining and data acquisition.
@en
Consensus guidelines for myelo ...... staining and data acquisition.
@en-gb
type
label
Consensus guidelines for myelo ...... staining and data acquisition.
@ast
Consensus guidelines for myelo ...... staining and data acquisition.
@en
Consensus guidelines for myelo ...... staining and data acquisition.
@en-gb
prefLabel
Consensus guidelines for myelo ...... staining and data acquisition.
@ast
Consensus guidelines for myelo ...... staining and data acquisition.
@en
Consensus guidelines for myelo ...... staining and data acquisition.
@en-gb
P2093
P2860
P356
P1476
Consensus guidelines for myelo ...... staining and data acquisition.
@en
P2093
Alberto Orfao
Bruno Paiva
Jeffrey L Jorgensen
Lloyd Stoolman
Maryalice Stetler-Stevenson
P2860
P356
10.1002/CYTO.B.21249
P577
2015-04-23T00:00:00Z